Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application.

Bai L, Chen W, Chen J, Li W, Zhou L, Niu C, Han W, Cui J.

J Transl Med. 2017 Feb 27;15(1):51. doi: 10.1186/s12967-017-1152-5. Review.

2.

Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists.

Manrique SZ, Dominguez AL, Mirza N, Spencer CD, Bradley JM, Finke JH, Lee JJ, Pease LR, Gendler SJ, Cohen PA.

Oncotarget. 2016 Jul 12;7(28):42919-42942. doi: 10.18632/oncotarget.10190.

3.

CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.

Jordan M, Waxman DJ.

Cancer Lett. 2016 Apr 1;373(1):88-96. doi: 10.1016/j.canlet.2015.11.029. Epub 2015 Dec 3.

4.

In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.

Hammerich L, Binder A, Brody JD.

Mol Oncol. 2015 Dec;9(10):1966-81. doi: 10.1016/j.molonc.2015.10.016. Epub 2015 Nov 10. Review.

5.

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.

Sagiv-Barfi I, Kohrt HE, Czerwinski DK, Ng PP, Chang BY, Levy R.

Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):E966-72. doi: 10.1073/pnas.1500712112. Epub 2015 Feb 17.

6.

Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma.

Sagiv-Barfi I, Kohrt HE, Burckhardt L, Czerwinski DK, Levy R.

Blood. 2015 Mar 26;125(13):2079-86. doi: 10.1182/blood-2014-08-593137. Epub 2015 Feb 6.

7.

Current clinical trials testing combinations of immunotherapy and radiation.

Crittenden M, Kohrt H, Levy R, Jones J, Camphausen K, Dicker A, Demaria S, Formenti S.

Semin Radiat Oncol. 2015 Jan;25(1):54-64. doi: 10.1016/j.semradonc.2014.07.003. Review.

8.

Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.

Singh M, Khong H, Dai Z, Huang XF, Wargo JA, Cooper ZA, Vasilakos JP, Hwu P, Overwijk WW.

J Immunol. 2014 Nov 1;193(9):4722-31. doi: 10.4049/jimmunol.1401160. Epub 2014 Sep 24.

9.

Intratumoral immunization: a new paradigm for cancer therapy.

Marabelle A, Kohrt H, Caux C, Levy R.

Clin Cancer Res. 2014 Apr 1;20(7):1747-56. doi: 10.1158/1078-0432.CCR-13-2116.

10.

Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas.

Sheng Sow H, Mattarollo SR.

Oncoimmunology. 2013 Dec 1;2(12):e27058. Epub 2013 Nov 5. Review.

11.

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.

Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, Luong R, Rosenblum MD, Steinman L, Levitsky HI, Tse V, Levy R.

J Clin Invest. 2013 Jun;123(6):2447-63. Erratum in: J Clin Invest. 2013 Nov;123(11):4980.

12.

Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization.

Xiao H, Peng Y, Hong Y, Huang L, Guo ZS, Bartlett DL, Fu N, Munn DH, Mellor A, He Y.

J Immunol. 2013 Jun 1;190(11):5866-73. doi: 10.4049/jimmunol.1203470. Epub 2013 Apr 22.

13.

Lymphoma B-cell responsiveness to CpG-DNA depends on the tumor microenvironment.

Ben Abdelwahed R, Cosette J, Donnou S, Crozet L, Ouakrim H, Fridman WH, Sautès-Fridman C, Mahjoub A, Fisson S.

J Exp Clin Cancer Res. 2013 Apr 5;32:18. doi: 10.1186/1756-9966-32-18.

14.

TLR agonists: our best frenemy in cancer immunotherapy.

Kaczanowska S, Joseph AM, Davila E.

J Leukoc Biol. 2013 Jun;93(6):847-63. doi: 10.1189/jlb.1012501. Epub 2013 Mar 8. Review.

15.

Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice.

Domingos-Pereira S, Decrausaz L, Derré L, Bobst M, Romero P, Schiller JT, Jichlinski P, Nardelli-Haefliger D.

Mucosal Immunol. 2013 Mar;6(2):393-404. doi: 10.1038/mi.2012.83. Epub 2012 Sep 12.

16.

CpG plus radiotherapy: a review of preclinical works leading to clinical trial.

Mason KA, Hunter NR.

Front Oncol. 2012 Aug 14;2:101. doi: 10.3389/fonc.2012.00101. eCollection 2012.

17.

Active immunotherapy: current state of the art in vaccine approaches for NHL.

Palomba ML.

Curr Oncol Rep. 2012 Oct;14(5):433-40. doi: 10.1007/s11912-012-0255-7. Review.

18.

Immunotherapy for B-cell lymphoma: current status and prospective advances.

Hollander N.

Front Immunol. 2012 Jan 24;3:3. doi: 10.3389/fimmu.2012.00003. eCollection 2012.

19.

Adoptive cell therapy for lymphoma with CD4 T cells depleted of CD137-expressing regulatory T cells.

Goldstein MJ, Kohrt HE, Houot R, Varghese B, Lin JT, Swanson E, Levy R.

Cancer Res. 2012 Mar 1;72(5):1239-47. doi: 10.1158/0008-5472.CAN-11-3375. Epub 2012 Jan 9.

20.

Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma.

Qian J, Zheng Y, Zheng C, Wang L, Qin H, Hong S, Li H, Lu Y, He J, Yang J, Neelapu S, Kwak LW, Hou J, Yi Q.

Blood. 2012 Jan 5;119(1):161-9. doi: 10.1182/blood-2011-07-368472. Epub 2011 Nov 2.

Supplemental Content

Support Center